Rajiv Gandhi Cancer Institute & Research Centre

Rajiv Gandhi Cancer Institute and Research Centre (RGCIRC) is one of the largest and most respected dedicated cancer hospitals in Asia, located in Rohini, New Delhi. Founded in 1996 as a project of the Indraprastha Cancer Society and Research Centre — a not-for-profit public society — RGCIRC has grown from a 152-bed facility into a 302-bed quaternary cancer care centre that diagnoses and treats approximately 60,000 patients annually.

In October 2016, the institute expanded significantly with the inauguration of a second campus in NitiBagh, South Delhi, adding 500 more beds to its capacity. The two campuses together make RGCIRC one of the most comprehensive dedicated cancer networks in northern India, capable of managing the complete spectrum of oncological conditions through surgery, medical oncology, radiation oncology, and bone marrow transplantation.

RGCIRC's clinical excellence is matched by its robust research programme. The institute conducts active clinical trials across multiple cancer types and contributes substantially to oncology research in India. Its multidisciplinary tumour boards ensure that each patient's case is evaluated by specialists from surgery, medical oncology, radiation oncology, radiology, and pathology before a treatment plan is finalised — a model of care that optimises outcomes for complex cases.

RGCIRC provides comprehensive cancer care across all major tumour types and treatment modalities. Surgical oncology covers head and neck surgery, breast surgery, thoracic oncology, gastrointestinal oncology, gynaecological oncology, and urological oncology. The hospital's robotic surgical capabilities enable minimally invasive cancer surgery with precision and reduced recovery times.

Medical oncology delivers systemic cancer treatments including chemotherapy, immunotherapy, targeted therapy, and hormonal therapy tailored to individual patient and tumour profiles. The Radiation Oncology department offers advanced radiation techniques. Haematology and the Bone Marrow Transplant (BMT) unit provide comprehensive blood cancer management including leukaemia, lymphoma, and myeloma, with both autologous and allogeneic BMT capabilities, including MUD (Matched Unrelated Donor) transplants.

Specialised wards include a dedicated Thyroid Ward and Leukemia Ward. Supportive services encompass palliative care and pain management, cancer rehabilitation, nutritional oncology, and psycho-oncological support. The pathology and molecular diagnostics laboratory provides advanced tumour profiling for targeted therapy selection.

The Rohini main campus has 302 beds with dedicated oncology wards, surgical theatres equipped for open and robotic cancer surgery, advanced radiation oncology suites, and the Bone Marrow Transplant unit. The NitiBagh South Delhi campus adds 500 beds and extends the institute's reach into south Delhi.

The hospital's NABL-accredited laboratory delivers comprehensive haematology, biochemistry, microbiology, histopathology, flow cytometry, and molecular diagnostics. Imaging services include PET-CT scanning, MRI, CT, digital mammography, and nuclear medicine for cancer staging and treatment monitoring. The blood bank maintains constant availability for high-volume haematology-oncology procedures. A dedicated day-care oncology unit streamlines chemotherapy delivery, reducing unnecessary inpatient admissions. The pharmacy carries a full range of anti-cancer drugs including novel targeted and immunotherapeutic agents. ICU facilities serve surgical and post-transplant patients requiring critical care.

RGCIRC attracts cancer patients from across South Asia, the Middle East, and Africa, drawn by its combination of world-class oncological expertise and significantly lower costs compared to cancer treatment in the US, UK, or Gulf countries. Cancer surgery, chemotherapy, radiation therapy, and bone marrow transplantation are available at a fraction of Western prices without compromising clinical quality.

The hospital's international patient services team assists overseas patients with medical visa invitation letters, treatment planning consultations via telemedicine prior to arrival, airport coordination, and accommodation guidance near the Rohini campus. Delhi's Indira Gandhi International Airport connects directly to major international hubs worldwide. English-language clinical consultations are standard. The NitiBagh campus in South Delhi provides an alternative access point for patients staying in southern parts of the capital. RGCIRC's NABH accreditation and ISO certifications provide international patients with confidence in the institute's adherence to established quality and safety standards.

Rajiv Gandhi Cancer Institute and Research Centre holds NABH (National Accreditation Board for Hospitals and Healthcare Providers) accreditation — India's national standard for hospital quality and patient safety. The NABH-accredited Blood Bank operates under strict transfusion safety protocols, and the NABL-accredited laboratory ensures the highest analytical standards for cancer diagnostics. The institute also holds NABH Nursing Excellence certification and NABH Green OT (Operating Theatre) Certification.

RGCIRC is certified to ISO 9001 (quality management systems) and ISO 14001 (environmental management systems) — dual certifications that demonstrate the institute's commitment to both clinical excellence and environmental responsibility. These internationally recognised standards reflect systematic quality processes across patient care, research, and hospital administration. The institute's consistent quality record over nearly three decades has established it as a benchmark cancer institution in Asia, contributing to cancer treatment protocols and clinical research that benefits patients beyond its own walls.